Skip to the main content

Acta clinica Croatica, Vol. 57. No. 4., 2018.

Professional paper

https://doi.org/10.20471/acc.2018.57.04.18

The Role of E2/P Ratio in the Etiology of Fibrocystic Breast Disease, Mastalgia and Mastodynia

Milena Brkić ; Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
Svetlana Vujović ; Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
Miomira Ivović ; Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
Milina Tančić Gajić ; Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
Ljiljana Marina ; Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
Maja Franić Ivanišević ; Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia
Damir Franić orcid id orcid.org/0000-0002-8226-2340 ; Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; School of Medicine, University of Maribor, Maribor, Slovenia

Full text: english pdf 679 Kb

page 756-761

downloads: 882

cite

Abstract

The aim of the study was to assess the role of the estradiol and progesterone relationship during the late luteal phase and the occurrence of fibrocystic breast disease (FBD). The concentration of estradiol/progesterone was measured in the group of women with FBD as study group (n=50) and control group of women without FBD (n=40). All women had regular ovulation cycles. Blood samples for estradiol (E2), progesterone (P) and prolactin determination were obtained in the morning at 8 am on days 21 and 24 of menstrual cycle. Significant mastalgia and mastodynia history in women with FBD was obtained with yes or no questionnaire. FBD diagnosis was confirmed with ultrasound (size and number of simple cysts). In the control group, a reduced E2/P ratio was noticed from day 21 to day 24 of the cycle (from 14.8±11.5 pg/mL to 9.1±6.1 pg/mL; p<0.05), which was not recorded in the group of women with FBD (study group). Even the slightest disturbance of the E2/P ratio may contribute to the occurrence of FBD with clinical manifestations of mastalgia and mastodynia.

Keywords

Estradiol; Progesterone; Fibrocystic breast disease; Luteal phase

Hrčak ID:

217848

URI

https://hrcak.srce.hr/217848

Publication date:

1.12.2018.

Article data in other languages: croatian

Visits: 2.558 *